This is a promotional presentation from Pfizer. Lyrica® is licensed for the treatment of neuropathic pain in adults.
Contact Us

Manage your patients returning with back pain

Tell me more
close
painDETECT Instructions

What is the painDETECT?
The painDETECT is a validated screening tool used to indicate the likelihood of a neuropathic pain component in patients with chronic low back pain. How do you use the painDETECT?
The painDETECT is designed to be completed independently by patients prior, during or after their consultation; however you may choose to work through the questionnaire with your patient. All questions need to be answered in order for the final score to appear. For the question with the mannequin/pain drawing, please use the circles and arrows underneath to mark where the pain occurs and the direction in which it travels.
Understanding your patients final score

  1. At the end of the questionnaire, the result will be calculated automatically giving a total score
    out of 38 (sensitivity: 85%; specificity: 80%).
    • For a score between 0 and 12, a neuropathic pain component is unlikely (<15%)
    • For a score between 13 and 18, the result is unclear
    • For a score between 19 and 38, a neuropathic pain component is likely (>90%)
  1. Further background information about the painDETECT can be found here:
    http://www.ncbi.nlm.nih.gov/pubmed/17022849.
    1. Freynhagen R, Baron R, Gockel U, Tölle T R. (2006). CurrMed ResOpin, 22:1911-1920.
close

You are now leaving www.uk.lyrica.eu a Pfizer website. Links to all external websites are provided as a resource to the viewer. Pfizer accepts no responsibility for the content of the linked sites.